As part of MDF's countdown to the IDMC-10, we are introducing you to some of the international DM researchers who will attend the conference. Meet Dr. Bé Wieringa, MDF Lifetime Achievement awardee and leading investigator.
Several scientists have published the results of important DM research. Dr. Katharine Hagerman, PhD, Research Assistant at Stanford University, has provided MDF with lay summaries of some of this research.
The MDF Fund-a-Fellow program is designed to help attract new researchers to the DM field, increasing the knowledge and science available regarding myotonic dystrophy. We are pleased to announce this year’s award recipients!
Isis Pharmaceuticals, Inc. has initiated a Phase I/II trial for ISIS-DMPKrx in patients affected by myotonic dystrophy type 1 (DM1).
Dr. Tetsuo Ashizawa, MD, has focused his career on the search for DM treatments and care for those affected. His multi-disciplinary, patient-centric approach to care moves DM research out of the lab and into his clinic at the University of Florida.